| Previous Close | 104.28 |
| Open | 103.95 |
| Bid | 103.82 x 1800 |
| Ask | 103.85 x 800 |
| Day's Range | 103.61 - 104.42 |
| 52 Week Range | 92.35 - 120.92 |
| Volume | |
| Avg. Volume | 1,120,178 |
| Market Cap | 209.853B |
| Beta (5Y Monthly) | 0.50 |
| PE Ratio (TTM) | 18.12 |
| EPS (TTM) | 5.72 |
| Earnings Date | Jan 31, 2025 |
| Forward Dividend & Yield | 3.78 (3.62%) |
| Ex-Dividend Date | Mar 07, 2024 |
| 1y Target Est | 116.16 |
GlobeNewswireNovartis highlights new 96-week results from Phase III Scemblix® ASC4FIRST trial at ASH and late-breaking analysis from Phase III Kisqali® NATALEE trial at SABCS
Longer-term 96-week results from Scemblix® ASC4FIRST Phase III study in first-line Ph+ CML-CP to be presented following recent FDA approval based on 48-week data Late-breaking Kisqali®* 4-year analysis on distant disease-free survival in key subgroups with HR+/HER2- early breast cancer from Phase III NATALEE trial also to be presentedPipeline updates demonstrate advancement in research and development programs in hematologic diseases and cancers Basel, November 25, 2024 – Novartis will present d
Insider MonkeyAre Hedge Funds Banking on Novartis AG (NVS)’s Core Income Growth?
We recently published a list of 8 Most Promising Healthcare Stocks According to Hedge Funds. In this article, we are going to take a look at where Novartis AG (NYSE:NVS) stands against other most promising healthcare stocks according to hedge funds. The Healthcare Sector: Growth, Innovation, and the Impact of AI The healthcare sector depends […]
